Skip To Main Content
Mark Bower on Muck Rack

Mark Bower

As seen in: Color Research & Application, Nature, Wiley Online Library, BMC Cancer, The Drum, The Lancet, Cancer Discovery, Security Boulevard, Telegraph and Argus, DATAVERSITY and

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma

|
By Alessia Dalla Pria, Yiran Zhao, Alberto Giovanni Leone, Justin Weir, Krista Tuohinto, Päivi Ojala, Mark Bower, David J. Pinato, Claudia A. M. Fulgenzi, Ignazio Puccio
| Nature Verified
Abstract Kaposi’s sarcoma (KS) is the most common malignancy occurring in people living with HIV (PLWH). The clinical course of KS in PLWH established on combined anti-retroviral therapy (cART) resembles that of classic KS. To compare the clinical and biological characteristics of HIV-associated KS in patients with well-controlled viral infection (N = 21) and non-HIV-associated KS (N = 19).
Open in Who Shared Issue with article?

Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study

|
By Alessia Dalla Pria, Niroshan Dayalan, Alberto Giovanni Leone, Markus K Muller, Markus P. Müller, Adam Temple, Marcus Hentrich, Mark Bower, Pascal Migaud, Daniela Drauz, Claudia AM Fulgenzi, Kai Hosmann, Hartmut Stocker
| Nature Verified
HLH in adults is characterized by fever, cytopenias, hepatosplenomegaly and hyperferritinemia, and carries a high mortality rate [1, 2]. It can occur secondary to infections, autoimmune diseases or malignancies, most commonly of haematological origin [1, 2]. Early identification of the underlying trigger is critical, but the sepsis-like presentation often delays diagnosis and worsens outcomes [3].
Open in Who Shared Issue with article?

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial - BMC Cancer

|
By Robin Young Verified, Amanda Kirkham, Joshua Savage, Charlotte Gaskell, SArah Johnson, Sarah Johnson, David H. Dockrell, Mark Bower, Christine Bowman, Michael F Leahy, Penella Woll, Lucinda Billingham, Sarah Westwell
| BMC Cancer Verified
Between 15-Jun-2012 and 25-Sep-2018, 19 patients were recruited, 13 into phase I and 6 into phase II, of whom three in phase I did not start treatment and were not included in the final analysis (Fig. 1). Patient baseline characteristics of those who started treatment are described in Table 1. Median age was 44 years (range 33, 63) with 15/16 (94%) male, 13/16 (81%) performance status 0, and a median time from HIV diagnosis of 5.1 years (range 0.9, 25.4).
Open in Who Shared Issue with article?
See all 31 licensed articles (37 Total)